Los Angeles Capital Management LLC Has $27.52 Million Position in CVS Health Corporation $CVS

Los Angeles Capital Management LLC raised its stake in shares of CVS Health Corporation (NYSE:CVS) by 5.5% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 358,893 shares of the pharmacy operator’s stock after purchasing an additional 18,588 shares during the period. Los Angeles Capital Management LLC’s holdings in CVS Health were worth $27,524,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. Havemeyer Place LP acquired a new stake in shares of CVS Health during the 4th quarter valued at $42,000. Vestcor Inc boosted its stake in shares of CVS Health by 13.9% during the 4th quarter. Vestcor Inc now owns 41,949 shares of the pharmacy operator’s stock valued at $3,329,000 after buying an additional 5,108 shares during the period. MCF Advisors LLC lifted its stake in shares of CVS Health by 210.4% in the 4th quarter. MCF Advisors LLC now owns 4,600 shares of the pharmacy operator’s stock valued at $365,000 after purchasing an additional 3,118 shares during the last quarter. OneAscent Financial Services LLC lifted its stake in shares of CVS Health by 4.5% in the 4th quarter. OneAscent Financial Services LLC now owns 4,672 shares of the pharmacy operator’s stock valued at $371,000 after purchasing an additional 201 shares during the last quarter. Finally, Parallel Advisors LLC lifted its stake in shares of CVS Health by 43.4% in the 4th quarter. Parallel Advisors LLC now owns 11,609 shares of the pharmacy operator’s stock valued at $921,000 after purchasing an additional 3,516 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Health was upgraded to a Zacks Rank #2 (Buy), reflecting improved earnings optimism and adding to the bullish tone around the stock. Article Title
• Positive Sentiment: Broker sentiment remains constructive on CVS Health, with recent coverage pointing to favorable views from Wall Street analysts and broader confidence in the company’s outlook. Article Title
• Positive Sentiment: The managed-care group rallied after analysts cited softer medical cost and utilization trends across the sector, which can support margins and spill over positively to CVS Health. Article Title
• Neutral Sentiment: CVS Health highlighted community and affordable-housing projects in New Jersey and Massachusetts, underscoring its corporate social responsibility efforts, but these announcements are unlikely to move the stock materially. Article Title
• Neutral Sentiment: Media coverage noted CVS Health is up about 8.5% since its last earnings report and asked whether the rally can continue, mainly reflecting investor attention on post-earnings momentum rather than a new catalyst. Article Title
• Neutral Sentiment: CVS CEO comments on AI, “super apps,” and primary care suggest longer-term strategy focus, but there was no immediate financial update in the coverage. Article Title
• Neutral Sentiment: Additional community partnership news, including a job training lab in Lincoln Heights, is supportive of the brand but not a direct earnings driver. Article Title

Insider Buying and Selling at CVS Health

In related news, Director Larry Robbins sold 1,983,538 shares of CVS Health stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total value of $187,345,164.10. Following the transaction, the director owned 6,213,261 shares in the company, valued at $586,842,501.45. This trade represents a 24.20% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the transaction, the executive vice president owned 10,133 shares in the company, valued at $907,714.14. This trade represents a 87.28% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 3,441,551 shares of company stock worth $323,703,977 in the last quarter. Insiders own 0.85% of the company’s stock.

CVS Health Stock Performance

Shares of CVS opened at $96.11 on Monday. The company has a market capitalization of $122.62 billion, a PE ratio of 42.34, a price-to-earnings-growth ratio of 0.94 and a beta of 0.62. CVS Health Corporation has a one year low of $58.50 and a one year high of $98.43. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. The company’s fifty day moving average price is $84.13 and its 200 day moving average price is $80.04.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping the consensus estimate of $2.21 by $0.36. The firm had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, analysts expect that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were issued a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 2.8%. The ex-dividend date was Thursday, April 23rd. CVS Health’s dividend payout ratio (DPR) is 117.18%.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on CVS. TD Cowen lifted their price objective on shares of CVS Health from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, May 11th. The Goldman Sachs Group lifted their price objective on shares of CVS Health from $95.00 to $97.00 and gave the company a “buy” rating in a research note on Thursday, February 12th. HSBC lifted their price objective on shares of CVS Health from $83.00 to $85.00 and gave the company a “hold” rating in a research note on Tuesday, May 5th. Wolfe Research reduced their price objective on shares of CVS Health from $100.00 to $97.00 and set an “outperform” rating for the company in a research note on Monday, March 2nd. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on shares of CVS Health from $88.00 to $92.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Twenty-two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $99.88.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.